The World Health Organization's global strategy for prevention and assessment of HIV drug resistance

Antiviral Therapy

Volumn 13, Issue SUPPL. 2, 2008, Pages 1-13

  Bennett, Diane E ^a   Bertagnolio, Silvia ^a   Sutherland, Donald ^b   Gilks, Charles F ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

CROSS RESISTANCE; DRUG EFFICACY; DRUG POTENCY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD; WORLD HEALTH ORGANIZATION; ANTIVIRAL RESISTANCE; ARTICLE; DEVELOPING COUNTRY; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; EPIDEMIOLOGY; GENETICS; GENOTYPE; HEALTH; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS; INTERNATIONAL COOPERATION; MUTATION; PRACTICE GUIDELINE; PROGRAM DEVELOPMENT; PUBLIC HEALTH; VIROLOGY;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; GENOTYPE; HEALTH CARE SURVEYS; HEALTH POLICY; HIV; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NATIONAL HEALTH PROGRAMS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; VIRAL LOAD; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 47249109877     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Joint United Nations Programme on HIV/AIDS. Financial resources required to achieve universal access to HIV prevention, treatment, care and support. September 2007. (Accessed 3 April 2008.) Available from http://data.unaids.org/ pub/Report/2007/20070925_advocacy_grne2_en.pdf
2. World Health Organization, Joint United Nations Program on HIV/AIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report, April 2007. ISBN 978 92 4 159539 1:1-88. Available from http//www/who.int/hiv/mediacentre/ univeral_access_progress_report_en.pdf
3. World Health Organization. Working together for health. The World Health Report 2006. ISBN 978 92 4 156317 8. Available from http://www.who.int/ whr/2006/whr06_en.pdf
4. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
5. Joint United Nations Program on HIV/AIDS. The three ones in action. (Accessed 3 April 2008.) Available from http://data.unaids.org/publications/irc- pub06/jc935-3onesinaction_en.pdf
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access: recommendations for a public health approach. (Accessed 3 April 2008.) Available from http://www.who.int/hiv/pub/guidelines/adult/en/index.html
7. Medicines Sans Frontieres. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. Available from http://www.accessmed-msf.org/fileadmin/user_upload/diseases/hiv-aids/ Untangling_the_Web/UTW10_RSep_horizontal.pdf
8. Pinheiroa E, Wasanb A, Kimb JY, et al. Examining the production costs of antiretroviral drugs. AIDS 2006; 20:1745-1752.
9. Ford N, Wilson D, Costa CG, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 2007; 21 Suppl 4:S21-S29.
10. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452.
11. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007; 1-48. (Accessed 3 April 2008.) Available from http://www.who.int/hiv/pub/guidelines/hivstaging/en/index/html
12. Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 2006; 20:1497-1502.
13. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
14. Deeks SG. Antiretroviral treatment of HIV infected adults. Brit Med J 2006; 332:1489-1493.
15. Stanford University. Stanford HIV drug resistance website. (Accessed 3 April 2008.) Available from http://hivdb.stanford.edu/
16. Temesgen Z, Warnke D, Kasten MJ. Current status of antiviral therapy. Expert Opin Pharmacother 2006; 7:1541-1554.
17. Hammer SM, Saag MS, Schechter M, Montaner JSG, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006; 296:827-843.
18. Lee PK, Kieffer TL, Silicianoa RF, Nettles RE. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Ther 2006; 57:803-805.
19. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Accessed 10 October 2007.) Available from http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf
20. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-732.
21. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001; 26 Suppl 1:S25-S33.
22. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362:2002-2011.
23. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124:984-994.
24. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004; 36:1100-1102.
25. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr 2005; 40:294-300.
26. Bautista-Arredondo S, Mane A, Bertozzi SM. Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico. AIDS 2006; 20:101-109.
27. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programmes in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
28. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2006; 353:2325-2331.
29. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
30. Sow PS, Otieno LF, Bissagnene E, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings. J Acquir Immune Defic Syndr 2006; 44:262-267.
31. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 2006; 20:41-48.
32. Kinoti S, Tawfik L. The impact of HIV/AIDS on the health workforce in developing countries. Background paper prepared for the World Health Organization World Health Report 2006. Available from http://www.who.int/hrh/ documents/Impact_of_HIV.pdf
33. Sankar A, Golin C, Simoni JM, Luborsky M, Pearson CR. How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2006; 43:S54-S68.
34. + cell count responses. J Acquir Immune Defic Syndr 2005; 38:578-583.
35. Colebunders R, Kamya M, Semitala F, Castelvuovo B, Katabira E, McAdam K. Free antiretrovirals must not be restricted only to treatment-naive patients. PLoS Med 2005; 2:941-943.
36. Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42:252-259.
37. Bisson GP, Frank I, Gross R, et al. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 2006; 20:1333-1336.
38. Zachariah R, Harries AD, Manzi M, et al. Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS ONE 2006; 1:e121.
39. Kim JY, Farmer P. AIDS in 2006 - Moving toward one world, one hope? N Engl J Med 2006; 355:645-646.
40. Rowe KA, Makhubele B, Hargreaves JR, et al. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral therapy in resource-poor settings. Int J Tuberc Lung Dis 2005; 9:263-269.
41. Mukherjee JS, Ivers L, Leandre F. Antiretorivral therapy in resource-poor settings: decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr 2006; 43:S123-S126.
42. Okeke IN, Klugman KP, Bhutta ZA, et al. Antimicrobial resistance in developing countries. Part II: Strategies for containment. Lancet Infect Dis 2005; 5:568-580.
43. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noël JM, M'Bangué M. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis 2005; 41:108-111.
44. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311-1316.
45. Bangsberg DR. Adherence, viral suppression, and resistance to antiretroviral therapy. AIDS Read 2007; 17 Suppl 4:S11-S15.
46. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-971.
47. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access: recommendations for a public health approach. (Accessed 3 April 2008.) Available from http://www.who.int/hiv/pub/guidelines/ pmtct/en/index.html
48. Pearson CR, Micek M, Simoni JM, Matediana E, Martin DP, Gloyd S. Modified directly observed therapy to faciliate high active antiretroviral therapy adherence in Beira, Mozambique. J Acquir Immune Defic Syndr 2006; 43:S134-S141.
49. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12:83-88.
50. Culbert H, Tu D, O'Brien DP, et al. HIV Treatment in a conflict setting: outcomes and experiences from Bukavu, democratic republic of the Congo. PLoS Med 2007; 4:794-798.
51. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-1327.
52. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753-760.
53. Bisson GP, Gross R, Strom JB, et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006; 20:1613-1619.
54. Pillay D, Kityo C, Robertson V, et al. Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of combivir/tenofovir within the DART Trial. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 22-25 July 2007, Sydney, Australia. Poster 642.
55. Stafford K, Etienne M, Aina O, et al. Immunological improvement and viral suppression after the initiation of antiretroviral therapy (ART) in Zambia. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 22-25 July 2007, Sydney, Australia. Abstract CDB292.
56. Chappell BJ, Margot NA, Miller MD. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. AIDS 2007; 21:761-763.
57. Brief Summary of CHAI Second-Line Pricing Analysis. Available from http://www.clintonfoundation.org/pdf/chai-arv-price-analysis-082407.pdf
58. Johnson JA, Li J-f, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2006; 192:16-23.
59. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
60. McIntyre J. Preventing mother-to-child transmission of HIV: successes and challenges. BJOG 2005; 112:1196-1203.
61. McConnell MS, Stringer JSA, Kourtis AP, Weidle PJ, Eshleman SH. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? Am J Obstet Gynecol 2007; 197 Suppl 1:S56-S63.
62. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
63. Bobat R, Kiepiela P, Kindra G, et al. Resistance in ART-naïve paediatric subjects with chronic HIV-1 infection: experiences from a pilot study. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 22-25 July 2007, Sydney, Australia. Abstract TUPEB053.
64. Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 2007; 197:S42-S55.
65. World Health Organization. Antiretroviral therapy in infants and children: towards universal access. Available from http://www.who.int/hiv/pub/ guidelines/paediatric020907.pdf
66. Clinton Foundation. Antiretroviral price lists. Available from http://www.clintonfoundation.org/pdf/chai-arv-price-list-050807.pdf
67. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLOS Medicine 2006; 3:e124.
68. Blower S, Brodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19:1-14.
69. Vardavas R, Blower S. The emergence of HIV transmitted resistance in Botswana: "When will the WHO detection threshold be exceeded?". PLoS ONE 2007; 2:e152.
70. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
71. Eron JJ Jr, Bartlett JA, Santana JL, et al. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004; 37:1581-1583.
72. Back NK, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:4040-4049.
73. Bunnell R, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92.
74. Bunnell R, Mermin J, DeCock KM. HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA 2006; 296:855-858.
75. Holstad MM, DiIorio C, Magowe MK. Motivating HIV positive women to adhere to antiretroviral therapy and risk reduction behavior: the KHARMA Project. Online J Issues Nurs 2006; 11:5.
76. World Health Organization, UNAIDS. Guidance on provider-initiated HIV testing and counseling in health facilities. ISBN 978 92 4 159556 8:1-55. Available from http://www.who.int/hiv/pub/guidelines/pitc2007/en/index.html
77. Kennedy C, O'Reilly K, Medley A, Sweat M. The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care 2007; 19:707-720.
78. Glynn JR, Sonnenberg P, Nelson G, Besterd A, Shearerd S, Murray J. Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 goldminers over 10 years of follow-up. AIDS 2007; 21:625-632.
79. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
80. Hill A, Wood E. Balancing effectiveness and access to HIV treatment in the developing world. AIDS 2007; 21:361-363.
81. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
82. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 2008; 13 Suppl 2:49-57.
83. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2:25-36.
84. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13 Suppl 2:15-23.
85. Myatt M, Bennett DE. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 2008; 13 Suppl 2:37-48.
86. Hedt BL, Wadonda-Kabondo N, Makombe S, et al. Early warning indicators for HIV drug resistance in Malawi. Antivir Ther 2008; 13 Suppl 2:69-75.
87. World Health Organization. Patient monitoring guidelines for HIV care and antiretroviral therapy. (Accessed 3 April 2008.) Available from http://www.who.int/hiv/pub/guidelines/patientmonitoring.pdf
88. Coetzee D, Boulle A, Hildebrand K, Asselman V, Van Cutsem G, Goemaere E. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 2004; 18 Suppl 3:S27-S31.
89. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
90. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets - Infect Dis 2003; 3:345-353.
91. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Guidelines for conducting HIV sentinel serosurveys among pregnant women and other groups. (Accessed 3 April 2008.) Available from http://data.unaids.org/ Publications/IRC-pub06/jc954-ancserosurveys_guidelines_en.pdf?preview=true
92. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 Suppl 2:101-107.
93. Abegaz WE, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 2008; 13 Suppl 2:89-94.
94. Kamoto K, Aberle-Grasse J on behalf of Members of the Malawi HIV Drug Resistance Task Force. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008; 13 Suppl 2:83-87.
95. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008; 13 Suppl 2:95-100.
96. Somi G, Tibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13 Suppl 2:77-82.
97. Sirivichayakul S, Phanuphak P, Pankam T, O-Charoen R, Sutherland D, Ruxrungtham K. HIV drug resistance transmission threshold survey in Bangkok, Thailand. Antivir Ther 2008; 13 Suppl 2:109-113.
98. Nguyen HT, Duc NB, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 2008; 13 Suppl 2:115-121.
99. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance among drug-naive HIV-1 recently infected individuals in South Africa. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 640.
100. Sirivichayakul S, Phanuphak P, Pankam T, O-Charoen R, Bennett DE, Ruxrungtham K. HIV drug resistance transmission threshold survey in high- and low-risk populations in Bangkok. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 640.
101. Somi G, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 655.
102. Aberle-Grasse J. HIV drug resistance surveillance in a national ART program. 1st HIV/AIDS Implementers' Meeting. 16-19 June 2007, Kigala, Rwanda. Abstract 358.
103. Nguyen HT, Nguyen D, Tuan AT, et al. HIV drug resistance threshold survey, Hanoi, Vietnam. 1st HIV/AIDS Implementers' Meeting. 16-19 June 2007, Kigala, Rwanda. Abstract 825.
104. Somi G, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. 1st HIV/AIDS Implementers' Meeting 2007. 16-19 June, Kigala, Rwanda. Abstract 207.
105. Bussmann H, de la Hoz Omez F, Roels TH, et al. Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-TS conducted during the 2005 Botswana sentinel survey. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. 22-25 July 2007, Sydney, Australia. Abstract TUPEB041.
106. Shafer RW, Rhee S-Y, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-221.
107. Shafer RW, Rhee S-Y, Bennett DE. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther 2008; 13 Suppl 2:59-68.